title: [Long-term psoriasis treatment].
authors.affiliation: Service de Dermatologie, Hôpital Édouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 3, France. denis.jullien@chu-lyon.fr
authors.forename: D
authors.initials: D
authors.lastname: Jullien
authors.forename: Maxime
authors.initials: M
authors.lastname: Battistella
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001691:Biological Therapy; D003289:Convalescence; D000068800:Etanercept; D005500:Follow-Up Studies; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007239:Infections / Q000139:chemically induced; D000069285:Infliximab; D008223:Lymphoma / Q000139:chemically induced; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D009369:Neoplasms / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept